Prognostic value of baseline metabolic tumor volume in early-stage Hodgkin lymphoma in the standard arm of the H10 trial
Prognostic value of baseline metabolic tumor volume in early-stage Hodgkin lymphoma in the standard arm of the H10 trial
复制标题
DOI：
10.1182/blood-2017-07-795476
复制
发表时间：
2018-03-29
期刊：
影响因子：
20.3
通讯作者：
Meignan, Michel
中科院分区：
文献类型：
--
作者：
Cottereau, Anne-Segolene;Versari, Annibale;Meignan, Michel
我们测试了基线正电子发射断层扫描（PET）/计算机断层扫描（CT）作为总肿瘤负荷的衡量标准，以更好地识别早期霍奇金淋巴瘤（HL）的高危患者。入选H10试验（NCT 00433433）标准组（联合治疗）的I-II期HL患者，基线PET和2个周期多柔比星、博莱霉素、长春碱和达卡巴嗪治疗后的中期PET（iPET 2）可用。在基线PET上测量总代谢肿瘤体积（TMTV）。iPET 2结果报告为阴性（DS 1 -3）或阳性（DS 4 -5），采用Deauville量表（DS）。评估TMTV的预后价值，并与基线特征、分期分类和iPET 2进行比较。共有258例患者合格：101例有利，157例不利。中位随访时间为55个月，27例无进展生存期（PFS）和12例总生存期（OS）事件。TMTV是PFS（P < .0001）和OS（P = .0001）的预测因子，特异性分别为86%和84%。高TMTV（>147 cm 3）组（n = 46）的5年PFS和OS分别为71%和83%，而低TMTV组（n = 46）分别为92%和98%。
We tested baseline positron emission tomography (PET)/computed tomography (CT) as a measure of total tumor burden to better identify high-risk patients with early-stage Hodgkin lymphoma (HL). Patients with stage I-II HL enrolled in the standard arm (combined modality treatment) of the H10 trial (NCT00433433) with available baseline PET and interim PET (iPET2) after 2 cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine were included. Total metabolic tumor volume (TMTV) was measured on baseline PET. iPET2 findings were reported negative (DS1-3) or positive (DS4-5) with the Deauville scale (DS). The prognostic value of TMTV was evaluated and compared with baseline characteristics, staging classifications, and iPET2. A total of 258 patients were eligible: 101 favorable and 157 unfavorable. The median follow-up was 55 months, with 27 progression-free survival (PFS) and 12 overall survival (OS) events. TMTV was a prognosticator of PFS (P < .0001) and OS (P = .0001), with 86% and 84% specificity, respectively. Five-year PFS and OS were 71% and 83% in the high-TMTV (>147 cm(3)) group (n = 46), respectively, vs 92% and 98% in the low-TMTV group (